Emerging Evidence in Second-Line and Potential Considerations in First-Line aGC and GEJ cancers
Manage episode 347793308 series 3381434
Creato da ReachMD, autore scoperto da Player FM e dalla nostra community - Il copyright è detenuto dall'editore, non da Player FM, e l'audio viene riprodotto direttamente dal suo server. Clicca sul pulsante Iscriviti per rimanere aggiornato su Player FM, o incolla l'URL del feed in un altra app per i podcast.
CME credits: 0.25
Valid until: 21-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-in-second-line-and-potential-considerations-in-first-line-agc-and-gej-cancers/14038/
HER2 is an essential biomarker to be assessed in all patients with gastric/GEJ cancer. Its importance is not only related to its role as a therapeutic target for pathway inhibition, but also to its ability to anchor the application of non-HER2 pathway therapeutic strategies with direct and bystander impact in the tumor microenvironment. Join Drs. Janjigian and Klempner as they delve into historical and exciting emerging data that may well bring new hope to your patients with gastric/GEJ cancers.=
Valid until: 21-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-in-second-line-and-potential-considerations-in-first-line-agc-and-gej-cancers/14038/
HER2 is an essential biomarker to be assessed in all patients with gastric/GEJ cancer. Its importance is not only related to its role as a therapeutic target for pathway inhibition, but also to its ability to anchor the application of non-HER2 pathway therapeutic strategies with direct and bystander impact in the tumor microenvironment. Join Drs. Janjigian and Klempner as they delve into historical and exciting emerging data that may well bring new hope to your patients with gastric/GEJ cancers.=
847 episodi
))
